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case report
Oncogenic osteomalacia: loss 
of hypophosphatemia might be 
the key to avoid misdiagnosis
Osteomalacia oncogênica: a perda de fosfatemia pode 
ser a chave para evitar o diagnóstico incorreto 
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SUMMARY
Diagnosing oncogenic osteomalacia is still a challenge. The disorder is characterized by osteo-
malacia caused by renal phosphate wasting and low serum concentration of 1,25-dihydroxyvi-
tamin D3 occurring in the presence of a tumor that produces high levels of fibroblast growth 
factor 23. However, it is possible that the disease is much more misdiagnosed than rare. We 
present the case of a 42-year-old man with a long-term history of undiagnosed progressive 
muscle weakness. His laboratory results mainly showed low serum phosphate. Surgical re-
moval of a nasal hemangiopericytoma that had been diagnosed five years earlier, brought him 
to a symptom-free condition. Even though knowing the underlying etiology would explain his 
osteomalacia, the patient sought medical help from countless physicians for five consecutive 
years, and only after adequate treatment a rewarding outcome was achieved. Arq Bras Endocrinol 
Metab. 2012;56(8):570-3
SUMÁRIO
A osteomalacia oncogênica é um diagnóstico clínico desafiador, caracterizado pela perda renal 
de fosfato e baixos níveis de 1,25-di-hidroxivitamina D3, ocorrendo na presença de um tumor 
produtor de altos níveis de fator de crescimento de fibroblasto 23. No entanto, é possível que se 
trate muito mais de uma falha de diagnóstico clínico do que propriamente uma doença rara. Os 
autores relatam o caso de um homem de 42 anos com histórico de fraqueza muscular progres-
siva por cinco anos e restrição à cadeira de rodas, sem diagnóstico. Seus exames laboratoriais 
evidenciavam baixos níveis de fósforo. A remoção cirúrgica de um hemangiopericitoma de-
tectado previamente em cavidade nasal levou à resolução completa dos sintomas. Os autores 
enfatizam que, mesmo com a etiologia já evidenciada, o paciente consultou diversos clínicos 
no decorrer dos cinco anos até que fossem instituídos o diagnóstico e o tratamento adequados. 
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INTRODUCTION
Oncogenic osteomalacia is a rare but potentially life-threatening condition most often misdiagno-
sed and mistreated in clinical practice. The exact mech-
anisms implicated in the pathogenesis of oncogenic os-
teomalacia remain elusive. Recently, the identification 
of fibroblast growth factor-23 (FGF23) in oncogenic 
osteomalacia tumors led to new insights into the under-
standing of this phosphate-wasting disorder. It seems 
that FGF23, a phosphatonin that is overexpressed by 
tumor cells, is responsible for the lack of phosphate re-
absorption in the proximal tubule of the kidney, along 
with an inappropriately low level of 1,25-dihydroxyvi-
tamin D3 (1,2). 
Here, we report a case of confirmed tumor-
induced oncogenic osteomalacia with mRNA FGF23 
overexpression, highlighting the difficulty in diagnosing 
this disorder.
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CASE REPORT
At the age of 37, this Brazilian-white man was admit-
ted to our Otorhinolaryngological Unit due to epi-
sodic events of epistaxis and nasal obstruction. Clinical 
evalua tion revealed a mass in the nasal cavity, which was 
biopsied and the histological analysis revealed that the 
tumor corresponded to a nasal hemangioperycitoma. 
Unfortunately, the patient missed follow-ups for five 
consecutive years and did not return to check the re-
sults. Hence, other laboratory tests, such as the mea-
surement of serum phosphorus, were not requested. 
Meanwhile, he visited countless physicians complaining 
basically of general muscle weakness and pain, which 
gradually worsened, leading to progressive walking dif-
ficulty. Several treatment attempts to relief his symp-
toms repeatedly failed.
Five years later, the patient was re-admitted at the 
Emergency Room reporting progressive disability. He 
was a wheelchair-user, and was diagnosed with femur 
fragility fracture. There was progressive height loss, and 
significant bone deformity (Figure 1). At that moment 
(second hospitalization) a bone biopsy was carried out, 
showing mature bone tissue with irregular areas of oste-
oid and immature bone. He had no symptoms of malab-
sorption, and no family history of metabolic bone disease.
Physical examination revealed that his blood pres-
sure was 120/85 mmHg, and pulse was regular at 78 
beats per minute. Neurological examination showed re-
duction of reflexes. Muscle strength was graded IV/V 
on all four limbs. 
His laboratory tests showed calcium of 2.3 mmol/L 
(RV:2.1-2.6 mmol/L), creatinine level of 0.7 mg/
dL (61.88 μmol/L), low serum phosphorus of 0.51 
mmol\L (RV:0.81-1.45 mmol/L), PTH:53.3 pg/ml 
(11-65 pg/mL), inappropriately normal phosphaturia 
of 851.64 mg/24h (400-1,300 mg/24h), and low tu-
bular reabsorption of phosphate at 72% (normal range 
78-98%), thus indicating renal phosphate wasting. 
His 25-hydroxyvitamin D was normal, but 1,25-dihy-
droxyvitamin D3 level was also inappropriately normal 
(26 pg/mL; RV:9-52 pg/mL). 
As the biopsy performed 5 years earlier showed a na-
sal hemangioperycitoma, and taking into conside ration 
the clinical complaint of progressive muscle weakness 
and pain, the radiological evidence of osteomalacia, to-
gether with hyphophosphatemia and low tubular rea-
bsorption of phosphate, the hypothesis of underlying 
oncogenic osteomalacia was considered.
A new evaluation of the previously detected nasal 
cavity mass using computer tomography and magnetic 
resonance imaging confirmed the presence of the tu-
moral mass. An expanding lesion occupied almost the 
whole left (L) nasal cavity with solid ethmoidal cells 
on the left with heterogeneous intravenous contrast. 
Eroded bone walls from the L maxillary sinus, ethmoid 
and sphenoid bone, and L lamina papyracea were ob-
served. The mass measured 7X4X6 cm and extended to 
the interior of the rhinopharynx. Since we did not have 
access to either fgf23 serum level data, or information 
about other factors related to tumor-induced osteoma-
lacia, we opted to use a molecular biology tool in this 
case. The tumor was completely removed at that mo-
ment, and total RNA of the tumoral mass was extracted 
using Trizol reagent (Invitrogen). One microgram of 
total RNA was reverse-transcribed with SuperScript III 
First-Strand Synthesis System for Reverse Transcription 
(RT) PCR (Invitrogen, Cat. no.: 18080-051). 
Quantitative real-time PCR was used to study 
FGF23 mRNA expression. The real-time RT-PCR was 
carried out using the SYBR Green I chemistry method 
(SYBR Green Quantitect RT-PCR Kit, Applied Biosys-
tems). An ABI Prism 7700 system (PerkinElmer Life 
sciences, Boston, MA, USA) was employed to quanti-
tatively measure FGF23, and cyclophilin (internal con-
trol) mRNA expression. All assays were performed in 
duplicate. The mRNA contents were normalized to the 
cyclophilin mRNA levels, and differences in expression 
were determined by the Ct method described in the 
ABI user’s manual (Applied Biosystems). This assay 
showed overexpression of FGF23 mRNA in the tumor 
tissue compared to normal tissue (Figure 2). 
After complete resection of the nasal hemangioperi-
cytoma, the patient became symptom-free, laboratory 
parameters were normalized, and he noticed progres-
sive improvement of his muscle strength. 
Figure 1. Scoliosis, convex to the left, in the thoracic region. Radiolucent 
areas at the end of the clavicles.
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up requires numerous imaging procedures and modali-
ties (5). Even with modern techniques of molecular 
imaging, it is not easy to both locate and identify these 
tumors. Fortunately, in the case presented here, the tu-
mor had been previously identified, a fact that greatly 
facilitated us to establish the diagnosis of the mass, and 
the management of our patient.
Soft tissue and bone tumors of various types (heman-
giopericytomas, hemangiomas, giant cell tumors, os-
teoblastomas) have been associated with oncogenic 
osteomalacia. Among these tumors, hemangiopericyto-
mas are probably the most common neoplasms, but the 
incidence and prevalence rates are still unknown (3). 
Hemangiopericytomas usually present as slow-grow-
ing, painless masses. The diagnosis of hemangiopericy-
toma is mainly based on the presence of a special his-
tologic architecture, formed by small cells of uniform 
shape that are tightly packed, and surrounding vascular 
channels with very thin walls (6). 
FGF23 was originally identified as responsible for 
the autosomal dominant hypophosphatemic rickets (1), 
but it is also involved in the pathogenesis of oncogen-
ic osteomalacia (2). Previous studies have shown that 
ele vated FGF23 concentrations found in preoperative 
sera of patients with oncogenic osteomalacia normali-
ze after resection of the causative tumor. Additionally, 
specific study of FGF23 (serum level, immunostaining 
or mRNA expression in the neoplastic tissue) of the 
causative tumor might be useful clinical markers for the 
diagnosis and management of patients with oncogenic 
osteomalacia (7). 
Once the tumor is located, the treatment of choice 
is complete resection. Failure to normalize the associ-
ated oncogenic osteomalacia may be due to the pres-
ence of residual tumor, or an additional occult causative 
lesion. 
In conclusion, physicians should have heightened 
awareness in patients with long-term complaints of 
muscle weakness and pain/bone fractures, and should 
include oncogenic osteomalacia in their list of differen-
tial diagnosis. The documentation of low serum phos-
phorus levels and high phosphatonin enables a quite 
easy diagnosis of this condition. The measurement of 
serum FGF23 levels may further support the diagno-
sis of this tricky, and often inefficiently-handled, phos-
phate-wasting disorder. 
Disclosure: no potential conflict of interest relevant to this article 
was reported. 
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Figure 2. Relative FGF23 expression for normal (nasal tissue) and affected 
tissues (hemangyopericitoma). The mRNA expression was quantified by 
qPCR, and cyclophilin was used to normalize FGF23 expression. 
Differences in expression were determined by the Ct method (2DDCt) 
(Student’s t test; p < 0.05).
DISCUSSION
There are several case reports in clinical medicine con-
sidered as rare diseases, but the patient presented here 
might be much more a case of misdiagnosis than of 
another rare disease. Even though the patient had a 
previously known underlying etiology that could have 
explained his osteomalacia, he sought medical help 
from countless physicians for five consecutive years, and 
only after adequate treatment a rewarding outcome was 
achieved.
There is a range of metabolic bone disorders that 
lead to osteomalacia. They include inborn metabolism 
errors (autosomal dominant hypophosphatemic rickets, 
and X-linked hypophosphatemic rickets), malabsorp-
tion, and chronic renal disease (3). Oncogenic osteo-
malacia is considered a very rare cause of osteomalacia. 
This case report reinforces that oncogenic osteomala-
cia should be taken into consideration in patients with 
long-term complaints of muscle weakness or bone 
pain/fractures. The biochemical assessment reveals 
low serum phosphate in patients afflicted by oncogenic 
osteomalacia. Moreover, treating physicians should be 
aware of the paraneoplastic nature of this disorder, and 
should eagerly seek to locate the tumor site because 
tumor-resection may completely restore the functional 
capacity of the patient. 
Most commonly, mesenchymal tumors are respon-
sible for oncogenic osteomalacia. They are generally 
placed in the lower (45%) or upper (17%) extremities, 
and less often in the cranio-cervical region (4). It is 
usual ly very difficult to locate the tumor site, and work-
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